Elicio Therapeutics Inc. (ELTX)vsInsmed Inc (INSM)
ELTX
Elicio Therapeutics Inc.
$10.96
+3.89%
HEALTHCARE · Cap: $199.60M
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
ELTX leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
ELTX
Avoid16
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
No standout strengths identified
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ELTX
ELTX has a balanced fundamental profile.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : ELTX
The primary concerns for ELTX are Revenue Growth, EPS Growth, Market Cap.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
ELTX profiles as a value stock while INSM is a turnaround play — different risk/reward profiles.
ELTX carries more volatility with a beta of 1.68 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
ELTX generates stronger free cash flow (-7M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 16/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Elicio Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Elicio Therapeutics Inc. (ELTX) is a pioneering clinical-stage biotechnology company dedicated to revolutionizing cancer treatment through its innovative immunotherapies. Leveraging its proprietary Amphiphilic TLR9 Agonist (Eli-002), the company aims to elicit robust immune responses across a spectrum of cancer types, enhancing patient outcomes significantly. Elicio's strategic focus on personalized cancer vaccines and advanced immunotherapeutic approaches positions it to meet critical unmet medical needs in oncology, with ongoing clinical trials that underscore its commitment to transforming cancer care.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?